Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Effects of TNF-Alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
This study is currently recruiting participants.
Study NCT00477191 Information provided by Massachusetts General Hospital
First Received: May 18, 2007 Last Updated: May 24, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Psoriasis
Metabolic Syndrome
Hyperlipidemia
Obesity
Hypertension
Additional conditions recognized in this trial
Hyperlipidemias
Syndrome
More general conditions related to this trial
Body Weight
Cardiovascular Diseases
Disease
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Nutrition Disorders
Overnutrition
Overweight
Pathologic Processes
Signs and Symptoms
Skin Diseases
Skin Diseases, Papulosquamous
Vascular Diseases
Interventions listed in this trial
Etanercept (TNF-alpha antagonist)
Additional drug interventions recognized in this trial
TNFR-Fc fusion protein
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Gastrointestinal Agents
Immunologic Factors
Immunosuppressive Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Massachusetts General Hospital
Amgen
Back to top of Main Content
